Evidence map›Paper›PMID 39235729›Full record

ReviewCurrent cardiology reports2024

The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes.

Sushant Koirala, Michael Sunnaa, Thomas Bernier, Ahmet Afsin Oktay

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Psychological Distress and Disordered Eating in Adults Attending an Obesity Outpatient Clinic.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Article
  7. Genetic Predisposition to Prediabetes in the Kazakh Population.Current issues in molecular biology · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sushant KoiralaDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Michael SunnaaDepartment of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.
Thomas BernierDivision of Cardiology, Rush University Medical Center, Chicago, IL, 60612, USA.
Ahmet Afsin OktayDivision of Cardiology, Rush University Medical Center, Chicago, IL, 60612, USA. Ahmet_a_oktay@rush.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewCardiovascular disease (CVD) is the leading cause of death globally and is closely associated with obesity and type 2 diabetes mellitus (T2DM). This review examines the interplay between obesity, T2DM, and CVD, highlighting the increasing prevalence and economic burden of these conditions. RECENT

findingsPharmacologic therapies, particularly glucagon-like peptide-1 receptor agonists, show promise in substantial weight loss and subsequent reduction of adverse cardiovascular events in obese individuals with and without diabetes. Obesity significantly contributes to the development of insulin resistance and T2DM, further escalating CVD risk. The common co-occurrence of these three conditions may involve several other pathophysiological mechanisms, such as chronic inflammation, increased visceral adiposity, and endothelial dysfunction. Until recently, lifestyle modifications and bariatric surgery had been the primary methods for weight loss and mitigating obesity-associated cardiovascular risk. Newer pharmacological options have led to a paradigm shift in our approach to obesity management as they provide substantial benefits in weight loss, glycemic control, and cardiovascular risk reduction.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Heart Disease Risk FactorsObesityBariatric SurgeryGlucagon-Like Peptide-1 Receptor AgonistsHumansHypoglycemic AgentsInsulin ResistanceRisk FactorsWeight LossGlucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsCardiovascular diseaseDiabetes MellitusGlucagon-like peptide-1 receptor agonistObesityWeight loss

Identifiers

PMID39235729

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.